1
|
Marano F, Zunino V, Frairia R, Arvat E, Castellano I, Bosco O, Catalano MG, Fortunati N. Fibulin-1 interacts with Sex Hormone Binding Globulin and is linked to less aggressive estrogen-dependent breast cancers. Life Sci 2018; 207:372-380. [DOI: 10.1016/j.lfs.2018.06.024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Revised: 06/08/2018] [Accepted: 06/21/2018] [Indexed: 12/27/2022]
|
2
|
Hu J, Zhang A, Yang S, Wang Y, Goswami R, Zhou H, Zhang Y, Wang Z, Li R, Cheng Q, Zhen Q, Li Q. Combined effects of sex hormone-binding globulin and sex hormones on risk of incident type 2 diabetes. J Diabetes 2016; 8:508-15. [PMID: 26119029 DOI: 10.1111/1753-0407.12322] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/25/2015] [Revised: 05/31/2015] [Accepted: 06/16/2015] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND The aim of the present study was to investigate the combined effects of sex hormone-binding globulin (SHBG) and sex hormones on the risk of type 2 diabetes (T2D). METHODS A nested case-control study of Chinese participants in the Environment, Inflammation and Metabolic Diseases Study (2008-13) was performed. Of the 3510 subjects free of diabetes, 145 men and 87 women developed diabetes over the 5-year follow-up. One age- and sex-matched control subject was selected for each case. Baseline concentrations of SHBG, estradiol, testosterone, and dehydroepiandrosterone sulfate (DHEA-S) were divided into tertiles and subjects were classified as having low, intermediate and high levels accordingly. RESULTS After multivariate adjustment, men with low SHBG levels had a fourfold greater risk of T2D than men with high SHBG levels. Conversely, men with high estradiol levels had a fourfold greater risk of T2D than men with low estradiol levels. Men with low SHBG + high estradiol had a 20-fold greater risk of T2D than men with high SHBG + low estradiol (odds ratio [OR] 20.23; 95% confidence interval [CI] 4.62-51.33). These risk associations in men were not observed for testosterone or DHEA-S, alone or in combination with SHBG. Compared with low SHBG, the risk of T2D decreased with increasing SHBG tertile (OR 0.92 [95% CI 0.21-4.53], 0.14 [95% CI 0.10-0.74]; Ptrend = 0.043) after multivariate adjustment in women. Estradiol, testosterone, and DHEA-S levels showed no association with T2D in women. CONCLUSION Low SHBG in conjunction with high estradiol has an additive detrimental effect on the risk of T2D in men.
Collapse
Affiliation(s)
- Jinbo Hu
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Aiping Zhang
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Shumin Yang
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Yue Wang
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Richa Goswami
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Huang Zhou
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Yi Zhang
- Hospital of Chongqing University, Chongqing, China
| | - Zhihong Wang
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Rong Li
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Qingfeng Cheng
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Qianna Zhen
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Qifu Li
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| |
Collapse
|
3
|
Liao RS, Ma S, Miao L, Li R, Yin Y, Raj GV. Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. Transl Androl Urol 2016; 2:187-96. [PMID: 26816736 PMCID: PMC4708176 DOI: 10.3978/j.issn.2223-4683.2013.09.07] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Androgen receptor (AR)-mediated signaling is necessary for prostate cancer cell proliferation and an important target for therapeutic drug development. Canonically, AR signals through a genomic or transcriptional pathway, involving the translocation of androgen-bound AR to the nucleus, its binding to cognate androgen response elements on promoter, with ensuing modulation of target gene expression, leading to cell proliferation. However, prostate cancer cells can show dose-dependent proliferation responses to androgen within minutes, without the need for genomic AR signaling. This proliferation response known as the non-genomic AR signaling is mediated by cytoplasmic AR, which facilitates the activation of kinase-signaling cascades, including the Ras-Raf-1, phosphatidyl-inositol 3-kinase (PI3K)/Akt and protein kinase C (PKC), which in turn converge on mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) activation, leading to cell proliferation. Further, since activated ERK may also phosphorylate AR and its coactivators, the non-genomic AR signaling may enhance AR genomic activity. Non-genomic AR signaling may occur in an ERK-independent manner, via activation of mammalian target of rapamycin (mTOR) pathway, or modulation of intracellular Ca2+ concentration through plasma membrane G protein-coupled receptors (GPCRs). These data suggest that therapeutic strategies aimed at preventing AR nuclear translocation and genomic AR signaling alone may not completely abrogate AR signaling. Thus, elucidation of mechanisms that underlie non-genomic AR signaling may identify potential mechanisms of resistance to current anti-androgens and help developing novel therapies that abolish all AR signaling in prostate cancer.
Collapse
Affiliation(s)
- Ross S Liao
- Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
| | - Shihong Ma
- Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
| | - Lu Miao
- Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
| | - Rui Li
- Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
| | - Yi Yin
- Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
| | - Ganesh V Raj
- Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
| |
Collapse
|
4
|
Nyante SJ, Gammon MD, Kaufman JS, Bensen JT, Lin DY, Barnholtz-Sloan JS, Hu Y, He Q, Luo J, Millikan RC. Genetic variation in estrogen and progesterone pathway genes and breast cancer risk: an exploration of tumor subtype-specific effects. Cancer Causes Control 2014; 26:121-31. [PMID: 25421376 DOI: 10.1007/s10552-014-0491-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2013] [Accepted: 11/04/2014] [Indexed: 12/23/2022]
Abstract
PURPOSE To determine whether associations between estrogen pathway-related single nucleotide polymorphisms (SNPs) and breast cancer risk differ by molecular subtype, we evaluated associations between SNPs in cytochrome P450 family 19 subfamily A polypeptide 1 (CYP19A1), estrogen receptor (ESR1), 3-beta hydroxysteroid dehydrogenase type I (HSD3B1), 17-beta hydroxysteroid dehydrogenase type II (HSD17B2), progesterone receptor (PGR), and sex hormone-binding globulin (SHBG) and breast cancer risk in a case-control study in North Carolina. METHODS Cases (n = 1,972) were women 20-74 years old and diagnosed with breast cancer between 1993 and 2001. Population-based controls (n = 1,776) were frequency matched to cases by age and race. A total of 195 SNPs were genotyped, and linkage disequilibrium was evaluated using the r (2) statistic. Odds ratios (ORs) and 95 % confidence intervals (CIs) for associations with breast cancer overall and by molecular subtype were estimated using logistic regression. Monte Carlo methods were used to control for multiple comparisons; two-sided p values <3.3 × 10(-4) were statistically significant. Heterogeneity tests comparing the two most common subtypes, luminal A (n = 679) and basal-like (n = 200), were based on the Wald statistic. RESULTS ESR1 rs6914211 (AA vs. AT+TT, OR 2.24, 95 % CI 1.51-3.33), ESR1 rs985191 (CC vs. AA, OR 2.11, 95 % CI 1.43-3.13), and PGR rs1824128 (TT+GT vs. GG, OR 1.33, 95 % CI 1.14-1.55) were associated with risk after accounting for multiple comparisons. Rs6914211 and rs985191 were in strong linkage disequilibrium among controls (African-Americans r (2) = 0.70; whites r (2) = 0.95). There was no evidence of heterogeneity between luminal A and basal-like subtypes, and the three SNPs were also associated with elevated risk of the less common luminal B, HER2+/ER-, and unclassified subtypes. CONCLUSIONS ESR1 and PGR SNPs were associated with risk, but lack of heterogeneity between subtypes suggests variants in hormone-related genes may play similar roles in the etiology of breast cancer molecular subtypes.
Collapse
Affiliation(s)
- Sarah J Nyante
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA,
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Ma Y, Liang D, Liu J, Wen JG, Servoll E, Waaler G, Sæter T, Axcrona K, Vlatkovic L, Axcrona U, Paus E, Yang Y, Zhang Z, Kvalheim G, Nesland JM, Suo Z. SHBG is an important factor in stemness induction of cells by DHT in vitro and associated with poor clinical features of prostate carcinomas. PLoS One 2013; 8:e70558. [PMID: 23936228 PMCID: PMC3728318 DOI: 10.1371/journal.pone.0070558] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2012] [Accepted: 06/24/2013] [Indexed: 11/18/2022] Open
Abstract
Androgen plays a vital role in prostate cancer development. However, it is not clear whether androgens influence stem-like properties of prostate cancer, a feature important for prostate cancer progression. In this study, we show that upon DHT treatment in vitro, prostate cancer cell lines LNCaP and PC-3 were revealed with higher clonogenic potential and higher expression levels of stemness related factors CD44, CD90, Oct3/4 and Nanog. Moreover, sex hormone binding globulin (SHBG) was also simultaneously upregulated in these cells. When the SHBG gene was blocked by SHBG siRNA knock-down, the induction of Oct3/4, Nanog, CD44 and CD90 by DHT was also correspondingly blocked in these cells. Immunohistochemical evaluation of clinical samples disclosed weakly positive, and areas negative for SHBG expression in the benign prostate tissues, while most of the prostate carcinomas were strongly positive for SHBG. In addition, higher levels of SHBG expression were significantly associated with higher Gleason score, more seminal vesicle invasions and lymph node metastases. Collectively, our results show a role of SHBG in upregulating stemness of prostate cancer cells upon DHT exposure in vitro, and SHBG expression in prostate cancer samples is significantly associated with poor clinicopathological features, indicating a role of SHBG in prostate cancer progression.
Collapse
Affiliation(s)
- Yuanyuan Ma
- Department of Pathology, The Norwegian Radium Hospital, Institute of Clinical Medicine, Oslo University Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, Beijing, China
| | - Dongming Liang
- Department of Pathology, The Norwegian Radium Hospital, Institute of Clinical Medicine, Oslo University Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Jian Liu
- Department of Pathology, The Norwegian Radium Hospital, Institute of Clinical Medicine, Oslo University Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Jian-Guo Wen
- Department of Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Henan, China
| | - Einar Servoll
- Department of Surgery, Soerlandet Hospital, Arendal, Norway
| | - Gudmund Waaler
- Department of Surgery, Soerlandet Hospital, Arendal, Norway
| | | | - Karol Axcrona
- Departments of Urology, The Norwegian Radium Hospital, Oslo University Hospital, University of Oslo, Oslo, Norway
| | - Ljiljana Vlatkovic
- Department of Pathology, The Norwegian Radium Hospital, Institute of Clinical Medicine, Oslo University Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Ulrika Axcrona
- Department of Pathology, The Norwegian Radium Hospital, Institute of Clinical Medicine, Oslo University Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Elisabeth Paus
- Department of Medical Biochemistry, Oslo University Hospital, University of Oslo, Oslo, Norway
| | - Yue Yang
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery II, Peking University Cancer Hospital & Institute, Beijing, China
| | - Zhiqian Zhang
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cell Biology, Peking University Cancer Hospital & Institute, Beijing, China
| | - Gunnar Kvalheim
- Departments of Cell Therapy, The Norwegian Radium Hospital, Oslo University Hospital, University of Oslo, Oslo, Norway
| | - Jahn M. Nesland
- Department of Pathology, The Norwegian Radium Hospital, Institute of Clinical Medicine, Oslo University Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Zhenhe Suo
- Department of Pathology, The Norwegian Radium Hospital, Institute of Clinical Medicine, Oslo University Hospital, Faculty of Medicine, University of Oslo, Oslo, Norway
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Henan, China
- * E-mail:
| |
Collapse
|
6
|
Zuloaga KL, O’Connor DT, Handa RJ, Gonzales RJ. Estrogen receptor beta dependent attenuation of cytokine-induced cyclooxygenase-2 by androgens in human brain vascular smooth muscle cells and rat mesenteric arteries. Steroids 2012; 77:835-44. [PMID: 22542504 PMCID: PMC3809122 DOI: 10.1016/j.steroids.2012.04.013] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2012] [Revised: 04/06/2012] [Accepted: 04/10/2012] [Indexed: 12/31/2022]
Abstract
Androgens may provide protective effects in the vasculature under pathophysiological conditions. Our past studies have shown that dihydrotestosterone (DHT) decreases expression of cyclooxygenase-2 (COX-2) during cytokine, endotoxin, or hypoxic stimulation in human vascular smooth muscle cells, in an androgen receptor (AR)-independent fashion. Classically DHT is regarded as a pure AR agonist; however, it can be endogenously metabolized to 5α-androstane-3β, 17β-diol (3β-diol), which has recently been shown to be a selective estrogen receptor (ERβ) agonist. Therefore, we hypothesized that DHT's anti-inflammatory properties following cytokine stimulation are mediated through ERβ. Using primary human brain vascular smooth muscle cells (HBVSMC), we tested whether DHT's effect on IL-1β induced COX-2 expression was mediated via AR or ERβ. The metabolism of DHT to 3β-diol is a viable pathway in HBVSMC since mRNA for enzymes necessary for the synthesis and metabolism of 3β-diol [3alpha-hydroxysteroid dehydrogenase (HSD), 3β-HSD, 17β-HSD, CYP7B1] was detected. In addition, the expression of AR, ERα, and ERβ mRNA was detected. When applied to HBVSMC, DHT (10nM; 18 h) attenuated IL-1β-induced increases in COX-2 protein expression. The AR antagonist bicalutamide did not block DHT's ability to reduce COX-2. Both the non-selective estrogen receptor antagonist ICI 182,780 (1 μM) and the selective ERβ antagonist PHTPP (1 μM) inhibited the effect of DHT, suggesting that DHT actions are ERβ-mediated. In HBVSMC and in rat mesenteric arteries, 3β-diol, similar to DHT, reduced cytokine-induced COX-2 levels. In conclusion, DHT appears to be protective against the progression of vascular inflammation through metabolism to 3β-diol and activation of ERβ.
Collapse
MESH Headings
- Androgens/pharmacology
- Animals
- Blotting, Western
- Brain/cytology
- Cells, Cultured
- Cyclooxygenase 2/metabolism
- Cytokines/pharmacology
- Estrogen Receptor beta/genetics
- Estrogen Receptor beta/metabolism
- Humans
- In Vitro Techniques
- Male
- Mesenteric Arteries/drug effects
- Mesenteric Arteries/metabolism
- Muscle, Smooth, Vascular/cytology
- Muscle, Smooth, Vascular/drug effects
- Myocytes, Smooth Muscle/cytology
- Myocytes, Smooth Muscle/drug effects
- Myocytes, Smooth Muscle/metabolism
- Rats
- Rats, Sprague-Dawley
- Real-Time Polymerase Chain Reaction
- Receptors, Androgen/genetics
- Receptors, Androgen/metabolism
Collapse
Affiliation(s)
| | | | | | - Rayna J. Gonzales
- Corresponding author. Address: Department of Basic Medical Sciences, University of Arizona College of Medicine, 425 N. 5th Street, Building ABC1, Phoenix, AZ 85004-2157, United States. Tel.: +1 602 827 2143; fax: +1 602 827 2127. (R.J. Gonzales)
| |
Collapse
|
7
|
Osterlund KL, Handa RJ, Gonzales RJ. Dihydrotestosterone alters cyclooxygenase-2 levels in human coronary artery smooth muscle cells. Am J Physiol Endocrinol Metab 2010; 298:E838-45. [PMID: 20103743 PMCID: PMC2853212 DOI: 10.1152/ajpendo.00693.2009] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Both protective and nonprotective effects of androgens on the cardiovascular system have been reported. Our previous studies show that the potent androgen receptor (AR) agonist dihydrotestosterone (DHT) increases levels of the vascular inflammatory mediator cyclooxygenase (COX)-2 in rodent cerebral arteries independent of an inflammatory stimulus. Little is known about the effects of androgens on inflammation in human vascular tissues. Therefore, we tested the hypothesis that DHT alters COX-2 levels in the absence and presence of induced inflammation in primary human coronary artery smooth muscle cells (HCASMC). Furthermore, we tested the ancillary hypothesis that DHT's effects on COX-2 levels are AR-dependent. Cells were treated with DHT (10 nM) or vehicle for 6 h in the presence or absence of LPS or IL-1beta. Similar to previous observations in rodent arteries, in HCASMC, DHT alone increased COX-2 levels compared with vehicle. This effect of DHT was attenuated in the presence of the AR antagonist bicalutamide. Conversely, in the presence of LPS or IL-1beta, increases in COX-2 were attenuated by cotreatment with DHT. Bicalutamide did not affect this response, suggesting that DHT-induced decreases in COX-2 levels occur independent of AR stimulation. Thus we conclude that DHT differentially influences COX-2 levels under physiological and pathophysiological conditions in HCASMC. This effect of DHT on COX-2 involves AR-dependent and- independent mechanisms, depending on the physiological state of the cell.
Collapse
Affiliation(s)
- Kristen L Osterlund
- Dept. of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, USA
| | | | | |
Collapse
|
8
|
Ptak A, Gut P, Błachuta M, Rak A, Gregoraszczuk EŁ. Direct inhibition of ERK1/2 phosphorylation as a possible mechanism for the antiproliferative action of 3,4-diOH-PCB3 in the MCF-7 cell line. Toxicol Lett 2009; 190:187-92. [PMID: 19619627 DOI: 10.1016/j.toxlet.2009.07.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2009] [Revised: 07/08/2009] [Accepted: 07/10/2009] [Indexed: 11/16/2022]
Abstract
Our previously published data showed that 260h of exposure to 3,4-diOH-PCB3 decreased proliferation in the MCF-7 cell line. In the present study, we sought to determine whether this is due to action on the SHBG/cAMP/PKA system, activation of which can inhibit cell proliferation, or to direct inhibition of ERK1/2 phosphorylation. MCF-7 human breast cancer cells were treated for 72h with 4-monochlorobiphenyl (PCB3), 4'-hydroxy-4-monochlorobiphenyl (4-OH-PCB3) or 3'4'-dihydroxy-4-monochlorobiphenyl (3,4-diOH-PCB3) (300nM). After the completion of the treatment, cell proliferation was measured with a BrdU incorporation assay. SHBG, cAMP, PKA and ERK1/2 levels in the cells were determined via ELISA. PCB3 and 4-OH-PCB3 had no effect on extra- or intracellular SHBG levels, while a stimulation of SHBG intra- but not extracellular levels was noted in cells exposed to 3,4-diOH-PCB3. Both, pre- and co-incubation with SHBG decreased the proliferation of 3,4-diOH-PCB3-treated cells. Neither PCB3 nor its metabolite had an effect on the cAMP/PKA pathway. A decrease of both ERK1/2 forms was noted under the influence of 3,4-diOH-PCB3. In conclusion, the data presented clearly showed that the antiproliferative action of 3,4-diOH-PCB3 is not mediated by activation of the SHBG/AMP/PKA pathway, but many other plasma membrane receptors seem to be involved in the non-genomic action of 3,4-diOH-PCB3, and instead is due to direct inhibition of the ERK1/2 system.
Collapse
Affiliation(s)
- Anna Ptak
- Department of Physiology and Toxicology of Reproduction, Institute of Zoology, Jagiellonian University, 30-060 Kraków, Ingardena 6, Poland
| | | | | | | | | |
Collapse
|
9
|
Nakhla AM, Hryb DJ, Rosner W, Romas NA, Xiang Z, Kahn SM. Human sex hormone-binding globulin gene expression- multiple promoters and complex alternative splicing. BMC Mol Biol 2009; 10:37. [PMID: 19416531 PMCID: PMC2694190 DOI: 10.1186/1471-2199-10-37] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2008] [Accepted: 05/05/2009] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Human sex hormone-binding globulin (SHBG) regulates free sex steroid concentrations in plasma and modulates rapid, membrane based steroid signaling. SHBG is encoded by an eight exon-long transcript whose expression is regulated by a downstream promoter (P(L)). The SHBG gene was previously shown to express a second major transcript of unknown function, derived from an upstream promoter (P(T)), and two minor transcripts. RESULTS We report that transcriptional expression of the human SHBG gene is far more complex than previously described. P(L) and P(T) direct the expression of at least six independent transcripts each, resulting from alternative splicing of exons 4, 5, 6, and/or 7. We mapped two transcriptional start sites downstream of P(L) and P(T), and present evidence for a third SHBG gene promoter (P(N)) within the neighboring FXR2 gene; PN regulates the expression of at least seven independent SHBG gene transcripts, each possessing a novel, 164-nt first exon (1N). Transcriptional expression patterns were generated for human prostate, breast, testis, liver, and brain, and the LNCaP, MCF-7, and HepG2 cell lines. Each expresses the SHBG transcript, albeit in varying abundance. Alternative splicing was more pronounced in the cancer cell lines. P(L)- P(T)- and P(N)-derived transcripts were most abundant in liver, testis, and prostate, respectively. Initial findings reveal the existence of a smaller immunoreactive SHBG species in LNCaP, MCF-7, and HepG2 cells. CONCLUSION These results extend our understanding of human SHBG gene transcription, and raise new and important questions regarding the role of novel alternatively spliced transcripts, their function in hormonally responsive tissues including the breast and prostate, and the role that aberrant SHBG gene expression may play in cancer.
Collapse
Affiliation(s)
- Atif M Nakhla
- Department of Urology, Columbia University, New York, NY, 10032, USA
- Institute for Health Sciences, St Luke's-Roosevelt Hospital, 432 W 58th St Room 405, New York, NY, 10019, USA
| | - Daniel J Hryb
- Department of Urology, Columbia University, New York, NY, 10032, USA
- Institute for Health Sciences, St Luke's-Roosevelt Hospital, 432 W 58th St Room 405, New York, NY, 10019, USA
| | - William Rosner
- Institute for Health Sciences, St Luke's-Roosevelt Hospital, 432 W 58th St Room 405, New York, NY, 10019, USA
- Department of Medicine, Columbia University, New York, NY 10032, USA
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
| | - Nicholas A Romas
- Department of Urology, Columbia University, New York, NY, 10032, USA
- Institute for Health Sciences, St Luke's-Roosevelt Hospital, 432 W 58th St Room 405, New York, NY, 10019, USA
| | - Zhaoying Xiang
- Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY 10021, USA
| | - Scott M Kahn
- Department of Urology, Columbia University, New York, NY, 10032, USA
- Institute for Health Sciences, St Luke's-Roosevelt Hospital, 432 W 58th St Room 405, New York, NY, 10019, USA
- Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
| |
Collapse
|
10
|
Fu X, Zhu BT. Human pancreas-specific protein disulfide isomerase homolog (PDIp) is an intracellular estrogen-binding protein that modulates estrogen levels and actions in target cells. J Steroid Biochem Mol Biol 2009; 115:20-9. [PMID: 19429457 PMCID: PMC2680768 DOI: 10.1016/j.jsbmb.2009.02.008] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2008] [Revised: 02/05/2009] [Accepted: 02/09/2009] [Indexed: 11/26/2022]
Abstract
Earlier studies showed that protein disulfide isomerase (PDI), a well-known protein folding catalyst, can bind estrogens. Whether other PDI homologs can also bind estrogens, and if so, what are the biological functions of this unique property are not known at present and thus are the subjects of our present investigation. Here we report that, of the six representative PDI homologs examined (human PDI, PDIp, ERp57, ERp72, PDIA6 and rat PDIr), only the human pancreas-specific PDI homolog (PDIp) had a similar binding affinity for radiolabeled 17beta-estradiol (E(2)) as did PDI, with apparent K(d) values of 1.5+/-0.3 and 1.5+/-0.2microM, respectively. However, PDIp and PDI had distinctly different binding preference for several estrogen analogs. Moreover, we found that PDIp could serve as a high-capacity intracellular E(2)-binding protein and could modulate the intracellular concentrations of E(2) in cultured mammalian cells as well as in human pancreatic tissue. The PDIp-bound E(2) in a cell could be released following a drop in the extracellular E(2) concentrations, and the released E(2) could then augment estrogen receptor-mediated transcriptional activity. Notably, the estrogen receptor alpha and beta were also found to be expressed in rodent and human pancreatic tissues where high levels of PDIp were detected. Altogether, these data show that, in addition to its well-documented function as a protein folding catalyst, PDIp can also serve as an effective modulator of the cellular levels and biological actions of endogenous estrogens in certain target sites (such as the pancreas) where estrogen receptors and PDIp are co-present.
Collapse
Affiliation(s)
| | - Bao Ting Zhu
- To whom correspondence should be addressed at the Department of Pharmacology, Toxicology and Therapeutics, School of Medicine, University of Kansas Medical Center, MS-1018, room KLSIC-4061, 2146 W. 39th Ave, Kansas City, KS 66160, USA. PHONE: 913-588-9842. FAX: 913-588-7501. E-MAIL:
| |
Collapse
|
11
|
Osório-Costa F, Rocha GZ, Dias MM, Carvalheira JBC. Epidemiological and molecular mechanisms aspects linking obesity and cancer. ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA 2009; 53:213-26. [PMID: 19466214 DOI: 10.1590/s0004-27302009000200013] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2009] [Accepted: 02/15/2009] [Indexed: 02/07/2023]
Abstract
About 25% of cancer cases globally are due to excess weight and a sedentary lifestyle. These results are alarming, as the world knows a pandemic of obesity and, in consequence, insulin resistance. Obesity may increase risk for various cancers by several mechanisms, including increasing sex and metabolic hormones, and inflammation. Here, we present a review of epidemiological and molecular evidences linking obesity and cancer--particularly colorectal, post-menopausal breast, endometrial, pancreatic, high grade prostate, hepatocellular, gallbladder, kidney and esophageal adenocarcinoma. The expected striking increase in the incidence of cancer in the near future related to obesity turns the knowledge of this field of great impact as it is needed to the development of strategies to prevent and treat this disease.
Collapse
Affiliation(s)
- Felipe Osório-Costa
- Departamento de Clínica Médica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil
| | | | | | | |
Collapse
|
12
|
Alam SM, Rajendran M, Ouyang S, Veeramani S, Zhang L, Lin MF. A novel role of Shc adaptor proteins in steroid hormone-regulated cancers. Endocr Relat Cancer 2009; 16:1-16. [PMID: 19001530 PMCID: PMC2776657 DOI: 10.1677/erc-08-0179] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Tyrosine phosphorylation plays a critical role in growth regulation, and its aberrant regulation can be involved in carcinogenesis. The association of Shc (Src homolog and collagen homolog) adaptor protein family members in tyrosine phosphorylation signaling pathway is well recognized. Shc adaptor proteins transmit activated tyrosine phosphorylation signaling that suggest their plausible role in growth regulation including carcinogenesis and metastasis. In parallel, by sharing a similar mechanism of carcinogenesis, the steroids are involved in the early stage of carcinogenesis as well as the regulation of cancer progression and metastatic processes. Recent evidence indicates a cross-talk between tyrosine phosphorylation signaling and steroid hormone action in epithelial cells, including prostate and breast cancer cells. Therefore, the members of Shc proteins may function as mediators between tyrosine phosphorylation and steroid signaling in steroid-regulated cell proliferation and carcinogenesis. In this communication, we discuss the novel roles of Shc proteins, specifically p52(Shc) and p66(Shc), in steroid hormone-regulated cancers and a novel molecular mechanism by which redox signaling induced by p66(Shc) mediates steroid action via a non-genomic pathway. The p66(Shc) protein may serve as an effective biomarker for predicting cancer prognosis as well as a useful target for treatment.
Collapse
Affiliation(s)
- Syed Mahfuzul Alam
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198-5870, USA
| | | | | | | | | | | |
Collapse
|
13
|
Sendemir E, Herbert Z, Sivukhina E, Zermann DH, Arnold R, Jirikowski GF. Colocalization of Androgen Binding Protein, Oxytocin Receptor, Caveolin 1 and Proliferation Marker p21 in Benign Prostate Hyperplasia. Anat Histol Embryol 2008; 37:325-31. [DOI: 10.1111/j.1439-0264.2008.00848.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Foradori CD, Weiser MJ, Handa RJ. Non-genomic actions of androgens. Front Neuroendocrinol 2008; 29:169-81. [PMID: 18093638 PMCID: PMC2386261 DOI: 10.1016/j.yfrne.2007.10.005] [Citation(s) in RCA: 322] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2007] [Revised: 10/12/2007] [Accepted: 10/24/2007] [Indexed: 11/25/2022]
Abstract
Previous work in the endocrine and neuroendocrine fields has viewed the androgen receptor (AR) as a transcription factor activated by testosterone or one of its many metabolites. The bound AR acts as transcription regulatory element by binding to specific DNA response elements in target gene promoters, causing activation or repression of transcription and subsequently protein synthesis. Over the past two decades evidence at the cellular and organismal level has accumulated to implicate rapid responses to androgens, dependent or independent of the AR. Androgen's rapid time course of action; its effects in the absence or inhibition of the cellular machinery necessary for transcription/translation; and in the absence of translocation to the nucleus suggest a method of androgen action not initially dependent on genomic mechanisms (i.e. non-genomic in nature). In the present paper, the non-genomic effects of androgens are reviewed, along with a discussion of the possible role non-genomic androgen actions have on animal physiology and behavior.
Collapse
Affiliation(s)
- C D Foradori
- Department of Biomedical Sciences, Neurobiology Section, Colorado State University, Fort Collins, CO 80523, USA
| | | | | |
Collapse
|
15
|
Costantino L, Catalano MG, Frairia R, Carmazzi CM, Barbero M, Coluccia C, Donadio M, Genta F, Drogo M, Boccuzzi G, Fortunati N. Molecular mechanisms of the D327N SHBG protective role on breast cancer development after estrogen exposure. Breast Cancer Res Treat 2008; 114:449-56. [PMID: 18437557 DOI: 10.1007/s10549-008-0031-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2007] [Accepted: 04/15/2008] [Indexed: 10/22/2022]
Abstract
Sex Hormone-Binding Globulin, the specific carrier for sex steroids, regulates hormone bioavailable fraction and estrogen signaling system in breast cancer cells. A common single nucleotide polymorphism in the human SHBG gene results in an amino acid substitution (Asp327Asn), which introduces an additional N-glycosylation site, and is associated with reduced breast cancer risk in postmenopausal women. The frequency of this polymorphism was evaluated in a group of patients that developed breast cancer while taking hormonal replacement therapy (HRT) for menopause, an interesting model of estrogen exposure. The polymorphism frequency was significantly higher in women taking HRT that didn't develop any breast cancer than in breast cancer patients (P<0.05). To get insight into the underlying mechanisms, we compared the ability of recombinant wild type and variant (D327N) SHBG to influence estradiol effects in MCF-7 breast cancer cells. D327N SHBG was more effective than wild type protein in inhibiting estradiol-induced cell proliferation and anti-apoptosis. This depended on the fact that D327N SHBG binding to MCF-7 cells was significantly higher than that of wild type protein. As a consequence, D327N caused a larger induction of the second messenger cAMP and a deeper inhibition of the estradiol-induced Erk (1/2) phosphorylation. Our observations, demonstrating the increased efficiency of D327N SHBG in counteracting estradiol action and a significantly higher frequency of Asp327Asn polymorphism in women not developing breast cancer after estrogen exposure, first provide evidence for the mechanism of D327N SHBG protective action.
Collapse
Affiliation(s)
- Lucia Costantino
- Laboratory of Oncological Endocrinology, ASO San Giovanni Battista, Via Genova 3, Turin 10126, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Weiss J, Hancke K, Kreienberg R. Adipositas und maligne Erkrankungen. GYNAKOLOGISCHE ENDOKRINOLOGIE 2008. [DOI: 10.1007/s10304-007-0225-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Greendale GA, Palla SL, Ursin G, Laughlin GA, Crandall C, Pike MC, Reboussin BA. The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Am J Epidemiol 2005; 162:826-34. [PMID: 16177147 DOI: 10.1093/aje/kwi286] [Citation(s) in RCA: 84] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Mammographic density is an independent risk factor for breast cancer. In postmenopausal women, higher levels of endogenous sex steroids are associated with an increased risk of breast cancer. Limited prior data suggest that endogenous sex steroids either are not associated (total estradiol and progesterone) or are negatively associated (free estradiol) with higher mammographic density. To analyze the associations between endogenous sex steroids and mammographic density, the authors conducted a 1998-2005 cross-sectional analysis of baseline clinical trial data from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial for US women who had not used hormone therapy for at least 3.1 months prior to baseline. In models adjusted for age, body mass index, parity, prior use of hormone therapy, time since last use of hormone therapy, and the interaction between prior hormone therapy use and time since last hormone therapy use, higher levels of estrone (beta = 0.0013, p = 0.014), estradiol (beta = 0.0009, p = 0.009), and bioavailable estradiol (beta = 0.0021, p = 0.018) were statistically significantly related to greater mammographic density. (Beta coefficients express the increment in mammographic density per-unit increment (pg/ml) of each hormone.) These results suggest that some sex steroids may increase the risk of breast cancer by stimulating breast epithelial or stromal proliferation, which appears on a mammogram as higher density.
Collapse
Affiliation(s)
- Gail A Greendale
- Division of Geriatrics, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA 90095-1687, USA.
| | | | | | | | | | | | | |
Collapse
|
18
|
Sex-hormone binding globulin receptor-mediated growth inhibition in breast cancer cells: a proteomics approach. Breast Cancer Res 2005. [PMCID: PMC4233542 DOI: 10.1186/bcr1121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
19
|
Fortunati N, Frairia R. A new ELISA method to identify the D327N mutation of human sex hormone binding globulin (SHBG). J Endocrinol Invest 2003; 26:1100-4. [PMID: 15008248 DOI: 10.1007/bf03345257] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The D327N mutation of human SHBG is associated with a number of good prognostic factors in breast cancer like estrogen receptor positivity and erb2 negativity. The identification of this mutation, that requires only a small sample of circulating blood, could be helpful whenever tissue samples are too scanty for the determination of prognostic factors, e.g. at fine needle aspiration for cytology. The search for this mutation is routinely performed in our laboratory with the Hinfl restriction fragment length polymorphism (RFLP) technique on polymerase chain reaction (PCR)-amplified DNA. The present report describes a new and simple enzyme-linked immunosorbent assay (ELISA) method to detect the SHBG mutation. The DNA enzyme immuno assay (DEIA) method, that is widely used in virology and has already been used to identify single nucleotide mutations, allows the identification of hybrids between specific DNA sequences and biotynilated probes with a monoclonal antibody against double stranded-DNA. We here report that by using two specific probes, specifically built for this kind of test, one complementary to the wild type SHBG sequence and the other to the D327N mutated DNA, the DEIA technique can be used to identify on PCR-amplified DNA the D327N mutation of human SHBG exactly as the Hinfl RFLP technique. The DEIA technique could, thus, be especially helpful when a large number of samples has to be processed, the technique being easier than Hinfl RFLP, specific, reproducible and allowing substantial time saving.
Collapse
Affiliation(s)
- N Fortunati
- Laboratory of Oncologic Endocrinology, Department of Oncology, ASO San Giovanni Battista, Turin, Italy.
| | | |
Collapse
|
20
|
Heinlein CA, Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol 2002; 16:2181-7. [PMID: 12351684 DOI: 10.1210/me.2002-0070] [Citation(s) in RCA: 360] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
The biological activity of testosterone and dihydrotestosterone is thought to occur predominantly through binding to the androgen receptor (AR), a member of the nuclear receptor superfamily that functions as a ligand-activated transcription factor. However, androgens have also been reported to induce the rapid activation of kinase-signaling cascades and modulate intracellular calcium levels. These effects are considered to be nongenomic because they occur in cell types that lack a functional AR, in the presence of inhibitors of transcription and translation, or are observed to occur too rapidly to involve changes in gene transcription. Such nongenomic effects of androgens may occur through AR functioning in the cytoplasm to induce the MAPK signal cascade. In addition, androgens may function through the sex hormone binding globulin receptor and possibly a distinct G protein-coupled receptor to activate second messenger signaling mechanisms. The physiological effect of nongenomic androgen action has yet to be determined. However, it may ultimately contribute to regulation of transcription factor activity, including mediation of the transcriptional activity of AR.
Collapse
Affiliation(s)
- Cynthia A Heinlein
- George Whipple Laboratory for Cancer Research, Department of Pathology, University of Rochester, Rochester, New York 14642, USA
| | | |
Collapse
|
21
|
Reindollar R, Koltun W, Parsons A, Rosen A, Siddhanti S, Plouffe L. Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity. Fertil Steril 2002; 78:469-72. [PMID: 12215319 DOI: 10.1016/s0015-0282(02)03288-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To determine the effects of raloxifene hydrochloride, 60 mg/d, on serum levels of E(2), estrone, sex steroid-binding globulin, thyroxine-binding globulin, and follicle-stimulating hormone (FSH) in postmenopausal women. DESIGN Randomized placebo-controlled study at 16 centers in the United States. PATIENT(S) Ninety three women 42 to 80 years of age who were at least 2 years postmenopausal. INTERVENTION(S) Raloxifene (n = 47) or placebo (n = 46) for 3 months. MAIN OUTCOME MEASURE(S) Levels of E(2), estrone, sex steroid-binding globulin, thyroxine-binding globulin, and FSH were measured at baseline and after 3 months of therapy. RESULT(S) Raloxifene increased serum levels of sex steroid-binding globulin and thyroxine-binding globulin and decreased FSH levels compared with placebo. Levels of E(2) and estrone were unaffected. CONCLUSION(S) In postmenopausal women, raloxifene (60 mg/d) did not increase serum estrogen levels; however, it increased levels of sex steroid-binding globulin and thyroxine-binding globulin and decreased FSH levels.
Collapse
Affiliation(s)
- Richard Reindollar
- Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Inc, Boston, Massachusetts, USA
| | | | | | | | | | | |
Collapse
|
22
|
Abstract
This review will discuss the status of research related to sexual arousability. It will also present a model for sexual arousability based on current knowledge of steroids effects at the membranes of cells. Steroids have multiple rapid actions that are suggested to result from actions at membrane-associated receptors. When stimulated by steroids these receptors alter G-protein coupling in a manner unique to this complex. Initial stimulation of the receptors by steroids alters the coupling pattern of G-proteins and of other binding sites associated with the complex. This change in G-protein coupling is a stable alteration and thus may serve as a long-term change in the system, which is a requirement of sexual arousability. Stimulation of this receptor system by a surge of oxytocin at ejaculation or orgasm then decouples the G-protein and reduces arousability. Sex hormone binding globulin may be an important ligand at this complex. This model suggests completely new relationships among steroids and their receptors that may complement or diverge from actions at known intracellular receptors.
Collapse
Affiliation(s)
- Jack D Caldwell
- Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL 61107-1897, USA.
| |
Collapse
|
23
|
Becchis M, Frairia R, Ferrera P, Fazzari A, Ondei S, Alfarano A, Coluccia C, Biglia N, Sismondi P, Fortunati N. The additionally glycosylated variant of human sex hormone-binding globulin (SHBG) is linked to estrogen-dependence of breast cancer. Breast Cancer Res Treat 1999; 54:101-7. [PMID: 10424400 DOI: 10.1023/a:1006100929670] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Sex Hormone-Binding Globulin (SHBG), the plasma carrier for androgens and estradiol, inhibits the estradiol-induced proliferation of breast cancer cells through its membrane receptor, cAMP, and PKA. In addition, the SHBG membrane receptor is preferentially expressed in estrogen-dependent (ER+/PR+) breast cancers which are also characterized by a lower proliferative rate than tumors negative for the SHBG receptor. A variant SHBG with a point mutation in exon 8, causing an aminoacid substitution (Asp 327-->Asn) and thus, the introduction of an additional N-glycosylation site, has been reported. In this work, the distribution of the SHBG variant was studied in 255 breast cancer patients, 32 benign mammary disease patients, and 120 healthy women. The presence of the SHBG mutation was evaluated with PCR amplification of SHBG exon 8 and Hinf I restriction fragment length polymorphism (RFLP) procedure. This technique allowed us to identify 54 SHBG variants (53 W/v and 1 v/v) in breast cancer patients (21.2%), 5 variants (4 W/v and 1 v/v) in benign mammary disease patients (15.6%), and 14 variants (W/v) in the control group (11.6%). The results of PCR and RFLP were confirmed both by nucleotide sequence of SHBG exon 8 and western blot of the plasma SHBG. No differences in the mean plasma level of the protein were observed in the three populations. The frequency of the SHBG variant was significantly higher in ER+/PR+ tumors and in tumors diagnosed in patients over 50 years of age than in the control group. This observation suggests the existence of a close link between the estrogen-dependence of breast cancer and the additionally glycosylated SHBG, further supporting a critical role of the protein in the neoplasm.
Collapse
Affiliation(s)
- M Becchis
- Laboratorio di Endocrinologia, Dip. Fisiopatologia Clinica & II UOADU Medicina Generale, Azienda Ospedaliera S. Giovanni Battista, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Fortunati N. Sex hormone-binding globulin: not only a transport protein. What news is around the corner? J Endocrinol Invest 1999; 22:223-34. [PMID: 10219893 DOI: 10.1007/bf03343547] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The plasma Sex Hormone-Binding Globulin (SHBG) transports androgens and estradiol in the blood and regulates their bioavailable fraction and access to target cells. The recent advances in the knowledge of its structure and gene expression, and notabily the demonstration of a specific receptor (SHBG-R) located on membranes of sex steroid responsive cells, gave support to the thesis that SHBG has much more sophisticated functions at cell site. In particular, the receptor-mediated action of SHBG, which uses as a second messenger cAMP, has been linked to the effects of androgens and estradiol. It is conceivable that the SHBG/SHBG-R system works as an additional control mechanism which inhibits or amplifies the effects of DHT and estradiol in cells. In the prostate, it has been suggested that the estradiol-activated SHBG/SHBG-R complex cross-talks with the androgen receptor, and is able to activate AR even in the absence of DHT. Of great interest, for its potential clinical applications, is the observation that in estrogen-dependent breast cancer SHBG, through SHBG-R, cAMP and PKA, specifically inhibits the estradiol-induction of cell proliferation. This anti-proliferative, anti-estrogenic effect of human SHBG has not only increased and continues to increase our understanding of the molecular mechanisms involved in the biology of breast cancer, but could also be exploited as a future therapeutic strategy in the managing of estrogen-dependent tumours.
Collapse
Affiliation(s)
- N Fortunati
- Laboratorio di Endocrinologia, II UOADU Medicina Generale, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy
| |
Collapse
|
25
|
Affiliation(s)
- W Rosner
- Department of Medicine, St. Luke's/Roosevelt Hospital Center, New York, NY 10019, USA
| | | | | | | | | |
Collapse
|
26
|
Abstract
Incidences of breast, colorectal and prostate cancer are high in the Western world compared to countries in Asia. We have postulated that the Western diet compared to the semivegetarian diet in some Asian countries may alter hormone production, metabolism or action at the cellular level by some biochemical mechanisms. Our interest has been focused on two groups of hormone-like diphenolic phyto-oestrogens of dietary origin, the lignans and isoflavonoids abundant in plasma of subjects living in areas with low cancer incidence. The precursors of the biologically active compounds detected in man are found in soybean products, whole-grain cereal food, seeds, and berries. The plant lignan and isoflavonoid glycosides are converted by intestinal bacteria to hormone-like compounds. The weakly oestrogenic diphenols formed influence sex-hormone production, metabolism and biological activity, intracellular enzymes, protein synthesis, growth factor action, malignant cell proliferation, differentiation, cell adhesion and angiogenesis in such a way as to make them strong candidates for a role as natural cancer-protective compounds. Their effect on some of the most important steroid biosynthetic enzymes may result in beneficial modulation of hormone concentrations and action in the cells preventing development of cancer. Owing to their oestrogenic activity they reduce hot flushes and vaginal dryness in postmenopausal women and may to some degree inhibit osteoporosis, but alone they may be insufficient for complete protection. Soy intake prevents oxidation of the low-density lipoproteins in vitro when isolated from soy-treated individuals and affect favourably plasma lipid concentrations. Animal experiments provide evidence suggesting that both lignans and isoflavonoids may prevent the development of cancer as well as atherosclerosis. However, in some of these experiments it has not been possible to separate the phyto-oestrogen effect from the effect of other components in the food. The isoflavonoids and lignans may play a significant inhibitory role in cancer development particularly in the promotional phase of the disease, but recent evidence points also to a role in the initiation stage of carcinogenesis. At present, however, no definite recommendations can be made as to the dietary amounts needed for prevention of disease. This review deals with all the above-mentioned aspects of phyto-oestrogens.
Collapse
Affiliation(s)
- H Adlercreutz
- Department of Clinical Chemistry, University of Helsinki, Meilahti Hospital, Finland.
| | | |
Collapse
|
27
|
Nakhla AM, Romas NA, Rosner W. Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone-binding globulin. J Biol Chem 1997; 272:6838-41. [PMID: 9054366 DOI: 10.1074/jbc.272.11.6838] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
These experiments were designed to examine the relationship between the effects of steroid hormones mediated by classic intracellular steroid hormone receptors and those mediated by a signaling system subserved at the plasma membrane by a receptor for sex hormone-binding globulin. It is known that unliganded sex hormone-binding globulin (SHBG) binds to a receptor (RSHBG) on prostate membranes. The RSHBG.SHBG complex is rapidly activated by estradiol to stimulate adenylate cyclase, with a resultant increase in intracellular cAMP. In this paper we examine the effect of this system on a prostate gene product known to be activated by androgens, prostate-specific antigen. In serum-free organ culture of human prostates, dihydrotestosterone caused an increase in prostate specific antigen secretion. This event was blocked by the anti-androgens cyproterone acetate and hydroxyflutamide. In the absence of androgens, estradiol added to prostate tissue, whose RSHBG was occupied by SHBG, reproduced the results seen with dihydrotestosterone. Neither estradiol alone nor SHBG alone duplicated these effects. The estradiol.SHBG-induced increase in prostate-specific antigen was not blocked by anti-estrogens, but was blocked both by anti-androgens and a steroid (2-methoxyestradiol) that prevents the binding of estradiol to SHBG. Furthermore, an inhibitor of protein kinase A prevented the estradiol.SHBG-induced increase in prostate-specific antigen but not that which followed dihydrotestosterone. These data indicate that there is a signaling system that amalgamates steroid-initiated intracellular events with steroid-dependent occurrences generated at the cell membrane and that the latter signaling system proceeds by a pathway that involves protein kinase A.
Collapse
Affiliation(s)
- A M Nakhla
- Department of Medicine, St. Luke's/Roosevelt Hospital Center, New York, New York 10019 and the College of Physicians and Surgeons, Columbia University, New York, New York 10019, USA
| | | | | |
Collapse
|
28
|
Catalano MG, Comba A, Fazzari A, Benedusi-Pagliano E, Sberveglieri M, Revelli A, Massobrio M, Frairia R, Fortunati N. Sex steroid binding protein receptor (SBP-R) is related to a reduced proliferation rate in human breast cancer. Breast Cancer Res Treat 1997; 42:227-34. [PMID: 9065606 DOI: 10.1023/a:1005702009367] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
In the last years, an increasing amount of studies described a membrane receptor for the Sex Steroid Binding Protein (SBP) on several androgen-estrogen dependent tissues. One of the suggested biological roles of the interaction between SBP and its receptor seems to be a negative control of the E2 induced proliferation of human breast cancer cells through the cAMP pathway. In the present work, SBP membrane receptor was evaluated on human breast cancer specimens with a radio-binding assay. Each tissue sample was also evaluated for ER and PGR status. Cytosol Thymidine Kinase levels were measured in tissue samples in order to evaluate cell proliferation rate. SBP binding to membranes of ER +/PGR + samples was time and temperature dependent, specific and at high affinity. In addition, SBP recognized on breast cancer membranes two sites at different affinity, as previously described for other human tissues and cultured cells. Membrane SBP-R was detected in a significantly higher number of samples positive for both ER and PGR than in negative samples. SBP-R positive samples showed a significantly lower proliferation rate than SBP-R negative samples as demonstrated by TK activity. The present study contains evidences for the existence of a specific membrane receptor for SBP in breast cancer sample membranes and the presence of SBP-R seems to be strictly related to a lower proliferation rate of the sample.
Collapse
Affiliation(s)
- M G Catalano
- II Divisione Universitaria di Medicina Generale, Torino University Medical School, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Arnold SF, Collins BM, Robinson MK, Guillette LJ, McLachlan JA. Differential interaction of natural and synthetic estrogens with extracellular binding proteins in a yeast estrogen screen. Steroids 1996; 61:642-6. [PMID: 8916358 DOI: 10.1016/s0039-128x(96)00183-3] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
We have used the yeast estrogen (YES) consisting of the human estrogen receptor and a reporter containing two estrogen response elements linked to the lacZ gene to evaluate the interaction between ovarian, phyto-, and synthetic estrogens with extracellular binding proteins. YES was incubated with charcoal-stripped human serum, human sex hormone-binding globulin, or human alpha-fetoprotein in the presence of concentrations of various estrogens that induced a 100% estrogenic response, as measured by beta-galactosidase activity. The activity of estradiol and coumestrol, a phytoestrogen, was reduced 75% with physiological levels of serum, sex hormone-binding globulin, or alpha-fetoprotein. The beta-galactosidase activity of genistein, another phytoestrogen, also decreased with extracellular proteins but to a lower extent than estradiol. In contrast, the activity of the synthetic estrogens diethylstilbestrol, kepone, and p,'p-DDD was only minimally reduced with extracellular proteins. These results indicate a potential fundamental difference in the interaction of estrogens from diverse sources with extracellular binding proteins. This suggests that the capacity for various estrogens to induce estrogen-associated responses is in part regulated by their affinity for extracellular bindings proteins.
Collapse
Affiliation(s)
- S F Arnold
- Department of Environment Health Sciences, Tulane University, School of Public Health and Tropical Medicine, New Orleans, LA, USA
| | | | | | | | | |
Collapse
|